Summary of Disc Medicine FY Conference Call Company Overview - **Company**: Disc Medicine (NasdaqGM:IRON) - **Focus**: Development of therapies targeting red blood cell disorders through manipulation of iron and heme metabolism [2][3] Key Clinical Programs 1. **Bitopertin for Erythropoietic Protoporphyria (EPP)** - Selected for the Commissioner's National Priority Voucher program - Received a Complete Response Letter (CRL) from the FDA; the next step is the Phase 3 trial (APOLLO) data expected in Q4 2026 [4][5] - Anticipated approval by mid-2027 based on APOLLO trial results [14][16] 2. **DISC-0974 for Anemia of Myelofibrosis** - Aims to mobilize iron to treat anemia; pivotal trial design expected by the end of 2026 [5][6] - Phase 2 data shows significant potential with a 50% major response rate in patients [21][25] - Addressable market in the U.S. estimated at 22,000 patients, with a total addressable opportunity of over $4 billion [20] 3. **DISC-3405 for Polycythemia Vera (PV)** - Designed to restrict iron availability to control red blood cell production [27][28] - Phase 1 data indicates promising results; pivotal trial expected to start in the first half of 2027 [28][29] Financial Position - **Balance Sheet**: $791 million in cash, providing a runway into 2029 without assuming revenue from lead program approval [8][30] Market Potential - **Total Addressable Markets**: - EPP: Over $2 billion - Myelofibrosis: Over $4 billion - Polycythemia Vera: Over $7 billion [30] Regulatory and Development Challenges - The CRL for bitopertin highlighted the need for clinical benefit proof in the APOLLO trial [36] - The company is preparing for a Type A meeting with the FDA to discuss the CRL and trial design [34][35] Additional Insights - The company emphasizes capital efficiency and maintaining a lean operational structure while advancing drug development [63][65] - There is significant excitement within the patient community regarding the potential impact of their therapies [15] Conclusion Disc Medicine is positioned to address significant unmet needs in the treatment of red blood cell disorders with a robust pipeline and a strong financial foundation, despite facing regulatory hurdles. The upcoming data readouts and trial designs will be critical in shaping the company's future trajectory and market entry strategies.